TNFSF13B and autoimmune hepatitis: A key role of B cells in the pathogenesis of AIH is supported by the clinical observation that B cell depletion with rituximab, an anti-CD20 mAb, or belimumab, an anti-BAFF mAb, is an effective third-line therapy for patients who are difficult to treat (39–43).